A study published by Mike Dryden - one of the world's leading parasitologists - in Veterinary Parasitology has demonstrated that spinosad (Comfortis, Elanco) provides a high level of flea control one month after a single treatment and maintains a high level of effectiveness under conditions of natural challenge following subsequent monthly treatments.
The multi-clinic, investigator-blinded study1 was undertaken in client-owned dogs provided with three consecutive monthly treatments of oral spinosad (SPN) and fipronil/methoprene spot-on (FSM). All other household dogs and cats, to a maximum of four pets per household, were dispensed the same treatment. Subsequent treatments were given when the dog returned for whole-body flea counts and pruritus-scoring on days 30 and 60, with final assessments on day 90 (plus/minus five days on each occasion).
One hundred and twenty eight dogs were enrolled on the study at 10 veterinary practices in the USA (65 in the SPN arm and 63 in the FSM arm). On day 0, mean flea counts were 57.7 (range: 10-1469) and 44.8 (range: 10-717) for the SPN and FSM groups, respectively. On day 90, 55 of the 58 (95%) SPN dogs were flea free compared with only 21/55 or 38% of dogs in the FSM group. Mean pruritus scores declined to 0.92 (6.67 on day 0) in the SPN group and 3.83 (6.33 on day 0) in the FSM group by day 90. Mean flea counts were 0.08 and 5.19 for SPN and FSM groups respectively on day 90 correlating to a reduction in flea counts of 99.9% in the SPN dogs and 88.4% in the FSM dogs. Between treatment differences were found to be highly statistically significant (p<0.0001) for every parameter measured at every time point during the study in favour of SPN.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health said: "The recent study confirms oral spinosad's outstanding efficacy in controlling fleas and associated pruritus in dogs when administered by owners following natural challenge in the home environment".
For further information please contact your local Elanco Companion Animal Health key account manager or phone 01256 353131.
References
1 Assessment of owner-administered monthly treatments with oral spinosad or topical spot-on fipronil/(S)-methoprene in controlling fleas and associated pruritus in dogs. Michael W. Dryden, William G. Ryan, Margie Bell, Anthony J. Rumschlag, Lisa M. Young, Daniel E. Snyder. Veterinary Parasitology 191 (2013) 340-346
Boehringer Ingelheim has announced that its 'Talk About Laminitis' campaign will run from Mid March until the end of June.
Last year, the initiative saw over 9000 horses and ponies tested for PPID through its free ACTH test scheme. This year, to build on this success and support the testing of even more animals, the company has announced a high impact, co-ordinated campaign to drive awareness that up to 90% of laminitis cases may have an underlying endocrine cause1,2.
Once again, Boehringer is urging veterinary surgeons to carry out free ACTH blood tests on laminitic or foot-sore horses as part of the campaign, which is backed by Redwings, The British Horse Society and World Horse Welfare.
Professor Andy Durham from the Liphook Equine Hospital, where the ACTH tests are performed, said: "We are learning so much from these tests. For example, we are now recognising PPID routinely in laminitic horses and ponies as young as 10 years old, and in the spring when we might expect to see more EMS cases, where veterinary surgeons have also tested for PPID we are seeing both abnormally elevated ACTH and insulin. Unless the PPID is addressed, horses will continue to be at risk of painful recurrent laminitic episodes which is a significant welfare issue to the horse and extremely frustrating for owners."
To participate in the scheme, veterinary surgeons and horse owners can download ACTH blood test vouchers from www.talkaboutlaminitis.co.uk. Attach the voucher to the ACTH sample submission form and the ACTH laboratory fees will not be charged.
Lee Hackett from The British Horse Society said: "Without the 'Talk About Laminitis' initiative and the support of Boehringer Ingelheim, literally thousands of horses may not be receiving the appropriate treatment and management for their laminitis to help prevent recurrence. We hope as many veterinary surgeons as possible get involved this year to continue this welfare success."
To ensure that horse owners are fully aware of the initiative, a PR and advertising campaign in the equine consumer media will start in March. The ad campaign includes an infomercial on Horse & Country TV (SKY Channel 280), with viewer numbers in excess of 450,000 per month.
There will also be a live online broadcast for horse owners on endocrinopathic laminitis presented by David Rendle BVSc MVM CertEM(IntMed) DipECEIM MRCVS, from the Liphook Equine Hospital in Hampshire. The one-hour webinar, which takes place at 8.00pm on Wednesday 10 April, will educate horse owners on how the veterinary profession's understanding of this debilitating and devastating disease has been completely revolutionised over the past five years. It will be followed by an interactive Q&A session when viewers will be able to pose questions for David to answer.
David said: "As our knowledge of the two hormonal diseases responsible for the majority of cases of laminitis improves, veterinary surgeons can offer their clients more comprehensive advice on treatment options to prevent laminitis. For many owners who have struggled with this condition, this is an absolute revelation and has enormous welfare benefits".
Horse owners can register to view the online programme by visiting www.talkaboutlaminitis.co.uk.
To ensure that veterinary surgeons are versed in the most up to date research available, Boehringer Ingelheim will also be hosting a webinar for veterinary professionals at 8.00pm on Wednesday 13th March, presented by Professor Andy Durham BSc BVSc CertEP DEIM DipECEIM MRCVS. The online seminar, 'The laminitis revolution.... An update on our understanding of endocrinopathic causes of laminitis', will entitle the viewer to a downloadable certificate for one hour of CPD. To register, visit www.bi-academy.co.uk. Places are limited, so register early to avoid disappointment. The webinar will also be available to view after the event on demand.
For further information on how you can promote 'Talk About Laminitis' in your practice contact your Boehringer Ingelheim Territory Manager or call 01344 746959
1. Karikoski et al. (2011). The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital. Domestic Animal Endocrinology 41 111-117
2. Donaldson et al. (2004). Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis. J Am Vet Med Assoc;224:1123-1127.
Dr. Tracy Hill, a specialist in internal medicine, has joined the Royal (Dick) School of Veterinary Studies, bringing with her expertise in interventional radiology.
Tracy completed a fellowship in interventional radiology and endoscopy at the Animal Medical Centre in New York, will be researching new techniques in this developing field.
She will also work in the clinic at the School's Hospital for Small Animals and as a senior lecturer.
She said: "Interventional radiology is an emerging and expanding area in veterinary medicine. Interventional radiology employs the use of fluoroscopy and endoscopy to enable minimally invasive treatments for diseases in many body systems. These techniques often reduce morbidity, mortality, or cost associated with more invasive procedures. The Dick Vet has been performing interventional cardiac procedures for some time and we are looking to expand this field into treatment of non-cardiac diseases."
Tracy, who carried out her residency in small animal internal medicine at North Carolina State University, where she also completed a PhD, will help the Royal (Dick) School of Veterinary Studies at the University of Edinburgh to provide interventional radiology procedures.
This includes a minimally invasive treatment for certain liver shunts using a procedure only being regularly performed at a handful of veterinary hospitals in the world. In this procedure, fluoroscopic guidance is used to access the abnormal vessels in the abdomen via a catheter placed in the jugular vein in the neck. The abnormal shunt vessel is then closed using coil embolization, without the need for abdominal surgery.
Tracey said: "I am delighted to join the Dick Vet. There is no denying the expertise at the vet school, as well as its partnership with The Roslin Institute for research."
The PDSA has announced the launch of a new graduate programme to help train the veterinary surgeons of the future.
Applications for PDSA's Veterinary Surgeon Graduate Programme open today, and the programme is open to all veterinary surgeon graduates - including the current 2013 graduating student cohort.
According to the PDSA, its Veterinary Surgeon Graduate Programme is one of the first comprehensive - UK wide - graduate schemes in the veterinary profession to combine clinical experience, development of surgical skills, promotion of preventive services and pet wellbeing education. It is delivered via a structured programme with dedicated support including mentoring, training and continuing professional development opportunities - within a busy small animal charity practice environment.
Following the framework of the Royal College of Veterinary Surgeons (RCVS) Professional Development Phase (PDP), the duration of the programme is one year. Successful applicants will be based at one of five PDSA PetAid hospitals - Glasgow East, Bradford, Liverpool Kirkdale, Stoke-on-Trent or Bow - and will also work at several other PDSA PetAid hospitals within the geographic location, building up experience in different hospitals and working with different teams. There will also be dedicated time off the veterinary rota to be able to train and coach the new graduates to develop their clinical skills.
The charity says that the programme will provide the necessary experience for new graduates to complete their compulsory PDP. It is hoped that those successfully completing the graduate programme will continue their careers with PDSA taking on available permanent opportunities in the charity.
Richard Hooker, PDSA Director of Veterinary Services (pictured above left), said: "At PDSA, we have great talent within our veterinary teams and we are looking to add to that even further with the launch of our Veterinary Surgeon Graduate Programme; five outstanding graduates will join us in September 2013 to be part of PDSA's future and to develop their skills and experience as veterinary surgeons.
"On average, our PetAid hospitals see around 5,695 pets each working day - including consultations, emergency treatment, surgical procedures, through to preventative measures and education on pet wellbeing. The Veterinary Surgeon Graduate Programme will give our cohort the opportunity to gain invaluable small animal practice with the UK's leading veterinary charity, home to some of the most experienced and long-serving vets in our profession."
Applications are open until 29 March 2013. For further information and to apply, visit http://www.pdsa.org.uk/careers/graduate-programme/veterinary-graduates/apply-now or contact PDSA at hr.adminstration@pdsa.org.uk
Elanco Companion Animal Health has launched of Dexdomitor 0.1 mg/ml, adding to its range of alpha-2 agonists and antagonists.
Produced and manufactured in partnership with Orion Corporation, Elanco says Dexdomitor 0.1 mg/ml contains all the properties of dexmedetomidine in a formulation that allows accurate and convenient dosing for the smallest patients. It can be used as a sedative for non-invasive, mild to moderately painful procedures and examinations which require restraint, sedation and analgesia in dogs and cats. It can also be used for deep sedation and analgesia in dogs in concomitant use with butorphanol for medical and minor surgical procedures and as a pre-medication in dogs and cats before induction and maintenance of general anaesthesia.
Dexdomitor 0.1 mg/ml has been designed to provide accurate dosing in very small dogs (up to 5kg) for sedation and pre-medication, small to mid-size dogs (up to 20kg) for pre-medication, and small cats (up to 3kg) for sedation and pre-medication.
Ed Whittle MRCVS, technical consultant at Elanco Companion Animal Health said: "With nearly a quarter of dogs weighing less than 6kg and nearly three-quarters weighing less than 23.1kg1, Dexdomitor 0.1mg/ml is ideal for small animals that require low concentration doses of dexmedetomidine for convenient and accurate dosing".
Elanco has has also produced a sedation and pre-medication dosing guide to educate veterinary professionals on the recommended doses for its range of alpha-2 agonists and alpha-2 antagonists.
For further information contact your Elanco Companion Animal Health key account manager or email elancoCAH.uk@elanco.com.
The RCVS is to hold an online hustings on Tuesday, 19 March at 7pm to help voters decide who they wish to vote for in the upcoming RCVS Council elections, and is inviting members of the veterinary profession to suggest questions for the candidates to answer.
Gordon Hockey, RCVS Registrar said: "From feedback we've received, one of the reasons why people don't vote is because they know little about the candidates or their views. We hope this hustings will provide the candidates with a platform to address the veterinary electorate directly, and give voters the chance to put their own questions to those hoping to serve on Council."
The hustings will be run as a live webinar by 'The Webinar Vet' and will be free to listen to. However, the College says that due to the high number of candidates standing for election, it isn't possible to hold a debate, so questions should be submitted in advance (see below). Each candidate will be allocated around three minutes to introduce themselves and answer up to three questions of their choosing. The whole event will run for just under an hour.
Anthony Chadwick, who runs The Webinar Vet, will moderate proceedings, and Gordon Hockey will be on-hand to address any factual inaccuracies.
Veterinary surgeons can register to listen to the hustings at www.thewebinarvet.com/rcvs and submit their questions at the same time; alternatively, questions can be emailed to Ian Holloway at the RCVS (i.holloway@rcvs.org.uk).
Questions should be relevant to the role of the RCVS and the role of Council Members (see www.rcvs.org.uk/about). If questions should remain anonymous, please say so.
Ballot papers and candidates' biographies and manifestos are due to be posted on 7 March. Votes may be cast online, by text message or by post, by 5pm on Friday, 26 April 2013.
The RCVS Disciplinary Committee has reprimanded a veterinary surgeon for submitting a certificate of Clinical Inspection for Veterinary Inspectors ("TB52") for tuberculin tests he had undertaken on cattle, despite knowing that he had not fully complied with the standard operating procedures (SOP) for these tests.
At the outset of the three-day hearing, John Wilson admitted that, when acting as an Official Veterinarian (OV) he had not carried out tuberculin tests on cattle at a Wiltshire farm on 19 May 2011 strictly in accordance with the SOP required by the Animal Health and Veterinary Laboratories Agency (AHVLA), an executive agency of Defra.
The admitted shortcomings were that on 19 May, the second day of testing, Mr Wilson had failed to confirm the identity of all the animals, failed to inspect the animals digitally (ie using his hands) and had not measured the fold of skin at the injection site of all the animals. The College argued that this was contrary to the directions of the AHVLA and, in subsequently signing the TB52 certificate, he was either dishonest or should have known that the certification was incorrect. Mr Wilson admitted that he ought to have known the certification was incorrect but denied dishonesty, because he believed that he had conducted the test in a satisfactory manner and had correctly identified all the reactors in the herd.
Mr Wilson was a veterinary surgeon of over 40 years experience and unblemished record, and the Committee found his account of events to be accurate and honest. He said the farm involved was unprepared and test arrangements were chaotic, with poor handling facilities, and he would have been concerned for the safety of the animals and their handlers if he had complied fully with the SOP. He had advised the farmer to delay the test but his advice was rejected.
The Committee accepted that the testing had been carried out under exceptional and difficult circumstances. It noted that Mr Wilson had identified a reactor and taken appropriate actions, knowing that the outcome would be the quarantining of the whole herd. He had made no financial or other gain, other than the nominal fee charged for the work. Although failing to comply with the SOP fell short of what was expected of a veterinary surgeon, because of these circumstances, and as he had acted in what he considered to be the best interests of the animals and personnel, these actions did not amount to serious professional misconduct.
The Committee found that, even allowing for these difficulties and concerns, in signing the TB52 certificate a few days later, without any qualification, Mr Wilson ought to have known that it was incorrect, and his actions fell far short of the standards expected of the veterinary profession. They did not however find that he had been dishonest.
The Committee stressed the importance attached to accurate and reliable certification, in maintaining the confidence of the public and the profession, and in ensuring animal welfare.
Professor Lees, chairing and speaking on behalf of the committee said: "The Committee is aware, as confirmed by AHVLA, that this is a single, isolated event and the first offence in some 40 years of the Respondent working as a LVI [local veterinary inspector] or OV. After considering all the mitigating factors.and, given the exceptional circumstances of this specific case, the decision of the Committee is to reprimand Mr Wilson."
A new study1 published in the Equine Veterinary Journal's (EVJ) special American Association of Equine Practitioners supplement has concluded that maggots can play an integral role in modern veterinary care for a variety of wounds in horses.
The study assessed the efficacy of maggot debridement therapy in a diversity of equine lesions and found that the method was beneficial in 93% of cases.
Maggots have been used for the treatment of wounds for hundreds of years. Freshly emerged, germ-free larvae of the common green bottle fly are usually used for the purpose. Their wound-healing action is attributed to a debridement effect, an antiseptic effect, a direct effect on cytokine and cell proliferation involved in wound healing and breakdown of biofilm formation. Maggots also destroy and digest bacteria and may also be beneficial in the fight against multi-drug-resistant bacteria such as MRSA.
The study involved the retrospective analysis of 41 horses with various lesions including foot injury, limb laceration, soft tissue abscesses and musculoskeletal infection. Depending on the type, size and location of the wound the maggots were applied either in direct or indirect contact. In some cases a second maggot application was necessary to reach the desired level of healing. Debridement, disinfection and healing occurred in all but three cases, in less than a week. Of the three that did not respond two were complicated by the presence of tumours and one by pre-existing damage to the underlying bone.
Olivier Lepage of the University of Lyon, who led the study, said: "These results show that maggot debridement therapy potentially has an integral place in modern veterinary wound care. It can be used to treat many types of lesions, although not those involving tumours or bone sequestration. Associated high costs present a limiting factor but maggot debridement therapy should certainly be considered for lesions that fail to respond to conventional methods."
Professor Celia Marr, Editor of the EVJ, said: "Horses often suffer from non-healing wounds, particularly in the limbs where the skin is under continuous movement and there is very little subcutaneous tissue. Although at first glance this study might seem counter-intuitive and we might think of maggots as being the last thing one would want on a clean wound, it shows that maggots can be an effective way to clear damaged tissue and this is an important adjunctive approach in equine wound management."
1The use of maggot debridement therapy in 41 equids OM Lepage, A Doumbia, MF Perron-Lepage and M Gangl. EVJ ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00609.x
The study is published by Wiley-Blackwell and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.2042-3306.2012.00609.x/abstract
Vetoquinol - makers of the NSAID Cimalgex - has announced the launch of its updated website www.CiMyDog.co.uk.
The company says the website has been developed to provide reliable online information about pain in dogs to cater for the increasing needs of pet owners and vets.
The website has two sections. The first is a pet owner focussed, educational tool which takes the visitor on a journey through the process of pain; from spotting the signs of pain all the way through to ways of relieving pain, culminating in the recommendation that the visitor seeks advice from their veterinary practice.
The second section requires registration as it contains more in depth information on the pain process and potential treatment options available, this section is for veterinary professionals only. Also on this section of the website there are many scientific abstracts related to pain and treatment with links to enable the veterinary visitor can view this peer reviewed material.
Robert Simpson, Cimalgex Product Manager said: "The internet is a very powerful tool in terms of increasing education, especially in areas such as canine pain. Unfortunately there can also be a lot of misinformation online and so we felt it was important for Vetoquinol to try and redress the balance by producing www.CiMyDog.co.uk. This can be used as a reliable and up-to-date resource by pet owners and veterinary professionals alike. -
www.CiMyDog.co.uk is a very interactive site which aims to demystify the pain treatment process, ensure pet owners look out for behavioural signs of pain and looks to improve overall canine health with assistance from their veterinary practice. We hope that this will be a valuable resource to which vets can refer their pet owners."
The RCVS Disciplinary Committee has refused an application for restoration to the Register by Mr Joseph Holmes, who was struck off in 2011 for serious professional misconduct associated with surgery he had carried out on a dog and two cats.
At a two-week Disciplinary Committee hearing that concluded on 14 January 2011, two separate complaints had been considered against Mr Holmes, formerly of Waltham Veterinary Clinic, Grimsby. These involved a total of 31 charges, of which 28 were found to amount to serious professional misconduct. Mr Holmes was found to have advised on and undertaken surgical procedures without sufficient clinical grounds or consideration of alternative treatment options; failed to obtain the informed consent of his clients; undertaken procedures outside his area of competence; failed to refer or discuss the option of referral to a specialist; and, failed to provide his patients with adequate pain relief.
The then-Committee directed Mr Holmes' name be removed from the Register, whereupon he appealed to the Privy Council, who dismissed his appeal on 22 December 2011, concluding that removal from the Register "was the only disposal which could properly reflect the primary need to serve both the interests of animal welfare and the reputation of the veterinary profession".
At the hearing last week the Committee considered several factors in relation to Mr Holmes' application for restoration. Although Mr Holmes gave assurances that he accepted the findings of the original hearing, this contrasted completely to the robust way in which he had challenged all of these at that hearing and the majority in his appeal. Mr Holmes had been off the Register for only 12 months - just over the minimum period before an application for restoral was permitted. The Committee took the view that the application was premature and was not satisfied that Mr Holmes truly appreciated the seriousness of the findings made against him.
In response to questions from the Committee, Mr Holmes showed deficiencies in his knowledge, such as not knowing all of the constituents of the human drug, Anadin Extra, in spite of having produced a record of continuing professional development (CPD) on analgesia and having prescribed it to a dog in the original complaint. He did not provide records of CPD for 2010, 2011 and 2012, and although recognising that working in isolation from the majority of his fellow practitioners had contributed to his failures, he had made very limited efforts to observe first-opinion veterinary practice.
The Committee accepted at face value Mr Holmes' statement that he had not worked as a veterinary surgeon whilst de-registered, and accepted that removal from the Register had had a profound effect on Mr Holmes and his family, including the sale of his practice. It noted that Mr Holmes produced only the testimonials previously submitted to the Privy Council, which were of limited scope.
Professor Peter Lees, chairing and speaking on behalf of the Committee said: "Having regard to all the factors set out above, the Committee regrets that it is not satisfied that the applicant is fit to be restored to the Register. Accordingly, the application is refused."
The Animal Health Trust's (AHT) Dr Sue Dyson has been awarded a place in the International Equine Veterinarians Hall of Fame, in recognition of her contribution to hoof care in horses.
Sue, who is Head of Clinical Orthopaedics at the AHT, has lectured internationally and is known for both her clinical work with horses and an extensive research record, having published more than 200 refereed papers on lameness and diagnostic imaging in scientific journals. She has also co-authored several veterinary textbooks as well as training and competing as a high-level rider in international events.
Established in 1997, the International Equine Veterinarians Hall of Fame honours veterinary surgeons who have contributed to the knowledge and recognition of proper hoof care for horses. Vets are nominated either as practicing equine vets who work closely with farriers in the field, or as college and industry vets involved in teaching, research or other important aspects of equine veterinary and hoof care.
Anyone can nominate an equine vet for the award, which is sponsored by the American Farriers Journal, but selection is completed by previous inductees into the International Equine Veterinarians Hall of Fame. Awards are presented each year during the International Hoof-Care Summit in Cincinnati, Ohio.
Sue said: "I was completely surprised, but absolutely thrilled, to learn that I had been selected to join the distinguished list of people who have previously been appointed to the International Equine Veterinarians Hall of Fame.
"I think it is very humbling to recognise that, despite the knowledge that my team and I have amassed in the last 30 years, there is so much more to learn. From every new finding come many more questions. I hope that the enthusiastic dedication of my team will continue to result in learning and discovering more, and inspire others to do likewise, to the ultimate benefit of the welfare of our great friend, the horse."
Sue has has worked at the AHT for 30 years and is currently researching the association between hindlimb lameness and saddle slip. She has observed some association between the two for several years, however saddle slip has traditionally been attributed to an ill-fitting saddle, asymmetry of the horse's back shape or a crooked rider.
In 2011 Sue carried out a prospective research project with Intern Line Greve: 'Saddle slip may be an indicator of the presence of hindlimb lameness'. It was presented at the 51st Annual Congress of the British Equine Veterinary Association, Birmingham 2012, and identified that in some cases, saddle slip was directly linked to the presence of hindlimb lameness.
Research results showed that of 128 horses assessed for lameness grade and degree of saddle slip when ridden by two riders, the saddle consistently slipped to one side in 54% of the horses with hindlimb lameness, in comparison to just 4% of the horses with forelimb lameness. Diagnostic analgesia to abolish the hindlimb lameness eliminated the saddle slip in 97% of the horses observed in the study.
Sue and Line are currently undertaking further research to measure movement of the back, and forces under the saddle, with the aim of explaining biomechanically what is happening during the occurrence of saddle slip.
Bimeda has announced the UK launch of Selenate LA, for selenium deficiency in calves and adult cattle.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "The slow release product provides raised selenium levels for a full 12 month period. When injected, Selenate LA forms a reservoir under the skin and its low solubility sees an even release of selenium over a year. But it's not just the efficacy of Selenate LA that make it such a stand out product, it's the convenience too".
Bimeda says the health properties of Barium Selenate in selenium deficient herds are well documented, from prevention of white muscle disease, anoetrus and mastitis, to improved conception rates and milk yield¹.
However there are various choices for farmers when dealing with selenium deficiency.
Padraig said: "The beauty of Selenate LA is that it is one injection, once a year. You know exactly how much each cow is getting so it's very predictable. And with many farmers already time short, it makes selenium supplementation extremely straightforward and cost effective."
Selenate LA is a POM-V medicine and can be offered by veterinary surgeons based on serum levels of glutathione peroxidase from a representative sample of the herd, or as part of a herd health and fertility plan. Padraig said: "It allows vets to offer a cost-effective and licensed alternative to oral supplements, with the added piece of mind only an injection can bring.
"The long-lasting and effective levels of selenium allow injection of the dam at any time, including mid to late pregnancy, to ensure good selenium levels in the new-born calf. This also prevents those post-calving complications such as retained foetal membranes, metritis and poor calving to conception times, where selenium deficiency has been implicated".
The company confirms that there is no milk withdrawal period and a thirty one day meat withdrawal for the product. Selenate LA is administered via a subcutaneous injection from a multi-dose bottle. For further information contact Andrew Lane, Bimeda UK Sales Manager on 07917 208524.
1. 1987 (Taranaki, North Island)
Ceva Animal Health has launched a new TV advertising campaign designed to raise awareness of problems owners may face in a multi-cat environment.
The Cat Cabin Fever campaign will run for four weeks.
Ceva says the 20 second TV ads have been designed to strike a chord with viewers who have more than one cat in their household, where 'sometimes sharing just isn't an option'. Highlighted in particular is the Feliway Diffuser which releases natural pheromones into a room to help cats feel at ease, allowing them to cope with stressful situations and prevent unwanted behaviour. Malcolm Laurie, head of marketing at Ceva, said: "We know that there are more than 8million cats in the UK and only 2.5million cat households, therefore the majority of households must have more than one cat. "However, cats are solitary animals, which makes living with other cats difficult at times. This campaign is focused on making the lives of cat owners and their pets as harmonious as possible, including lots of top tips on how to ease any tensions in such an environment." Ceva has also produced a multi-cat leaflet designed to give owners specific advice on how to provide the correct environment for our feline friends The advertising campaign will be supported by online competitions, marketing materials for veterinary clinics and retailers, which include a checklist for a cat friendly home, and PR. For more information, visit: http://www.feliway.co.uk/.
The RCVS Disciplinary Committee has directed that a Leeds-based veterinary surgeon, whose convictions for threatening behaviour, theft, and assault made him unfit to practise, should be removed from the Register.
At the outset of the two-day hearing, Dr Gary Samuel admitted his convictions. These related to his actions near his property in Cardiff on 10 July 2011, and were received at Cardiff Magistrates' Court on 22 November 2011. The Committee was asked to decide if these convictions made Dr Samuel unfit to practise veterinary surgery, and to decide upon any sanction.
The facts of the offences, as set out at the magistrates' court by the prosecution, were that Dr Samuel took a camera and memory card from a neighbour who was taking photographs of construction works behind his property. In doing so, he grabbed the neighbour from behind, twisting her arm, and later threatened her and her partner with a large piece of wood.
Although Dr Samuel wrote to the College saying he had pleaded guilty to the charges, he also denied some of the offences charged, suggesting that it was the neighbour who had been abusive towards him.
The Committee allowed the possibility that Dr Samuel was provoked by the taking of photographs and may have been subjected to offensive abuse by the neighbour, and considered that he acted impulsively and lost control of his actions. However, the convictions were for serious offences: the assault resulted in injury to the victim; the threatening behaviour involved a risk of injury to the victim and her partner; and, the theft involved dishonesty. Dr Samuel's conduct at the time was "reckless", and he had since displayed very limited insight into his behaviour.
Professor Peter Lees, chairing and speaking on behalf of the Committee said: "The Committee considers that the offences of which the Respondent was convicted, and to which he pleaded guilty, were serious, as is reflected in the suspended sentences, community service orders, fines, restrictions and penalties imposed by the court. The Committee accepts that this is not a case in which the welfare of animals has been put at risk, but takes the view that a serious sanction is required in order to uphold the reputation of the veterinary profession, and public confidence in it, and to uphold proper standards of conduct and behaviour on the part of its members."
The Committee directed Dr Samuel's name should be removed from the Register.
Davies Veterinary Specialists (DVS), the private small animal referral centre based in Hertfordshire, has installed two new state-of-the-art ESAOTE ultrasound machines.
DVS says The MyLab Twice Vet and the MyLab Class C Vet provide fast, efficient and highly accurate imaging in a wide range of applications, including high-definition abdominal, cardiac, musculoskeletal and ophthalmic scans.
The MyLab Twice Vet, with its range of probes including the broadband 18MHz linear probe, will be used for general ultrasonographic imaging at DVS. It is capable of the most refined contrast media examinations that, for example, can help to locate and identify a liver tumour that may be rendered invisible when using conventional diagnostic procedures.
The MyLab Class C will be used predominantly for advanced cardiac work, including trans-oesophageal echocardiography for interventional procedures in theatre.
Pedro Oliveira, European Veterinary Specialist in Cardiology at DVS said: "The trans-oesophageal probe is currently a very rare piece of equipment in veterinary diagnostics. It gives us the capacity to obtain unique views of the heart, especially the heart base which can be a very difficult area to examine with regular echocardiography. It also allows real-time and direct monitoring of procedures, such as deployment of devices to occlude patent ductus arteriosus, surgery and anaesthesia in critical patients."
The first patient to benefit from the new My Lab Class C was an 11-year-old, female German shepherd dog with suspected cardiac neoplasia following several episodes of haemorrhage into the pericardium. A normal echocardiographic examination identified a small suspect area but it was in a part of the heart that was very difficult to approach surgically.
However, a trans-oesophageal examination revealed that another small mass close to the tip of the right auricle was actually the origin of the bleeding. The dog underwent surgery to remove the mass and subsequently made a full recovery. Without the My Lab Class C there would have been no viable options for this dog.
Clive Elwood, Managing Director at DVS, said: "Combining the best possible on-site diagnostic equipment with some of Europe's finest clinicians enables us to provide the best possible service and outcome for our patients, across multiple disciplines."
Researchers from the School of Veterinary Sciences at the University of Bristol have had a study into domestic dogs' fear responses to noise published in Applied Animal Behaviour Science.
According to the University, the study provides an important insight into dogs' fear of noises, and could improve our understanding of behavioural signs of fear or anxiety.
In the study two approaches were taken to investigate the occurrence of, and risk factors for, behaviours caused by a fear of noise: a postal survey of dog owners to investigate general demographic factors and a structured interview of a sub-set of owners to gather more detailed information.
It seems that while owners are often aware of their pet's behavioural response when exposed to a loud noise, they do not necessarily recognise it as being indicative of fear or anxiety. This has relevance both for awareness of compromised welfare, and the methodology for surveying such behaviour.
According to the researchers, other behavioural signs, such as decreased activity or salivation, may not be as easily recognised by owners as signs of fear, and may be under-reported. Also, signs of urination, salivation and destruction may make owners disappointed or angry, and this may influence their interpretation that such behaviours are associated with fearfulness.
The risk factors for owner-reported fear of noises included:
The researchers suggest a dog's early life experience is an important factor in the development of fear responses to specific loud noises.
Dr Rachel Casey, European Specialist in Veterinary Behavioural Medicine and Senior Lecturer in Companion Animal Behaviour and Welfare at Bristol University, said: "Our results suggest that the characteristics of dogs, their early environment, and exposure to specific loud noises are involved in the development of fear responses to noises. Interestingly, less than a third of owners sought professional advice about treatment for their pet's response to noises."
Disappointingly, less than a third of owners currently seek professional advice about treatment for their pet's fear. The researchers recommend there is a need for veterinary surgeons to increase awareness among the general dog owning public that treatment is both available and effective in dealing with fears of loud noises, and to direct them towards appropriate sources of help.
Information for vets and dog owners on finding an expert to help treat behaviour problems including fear of noises can be found at www.rspca.org.uk/findabehaviourist
Paper: Fear responses to noises in domestic dogs: Prevalence, risk factors and co-occurrence with other fear related behaviour, Emily J. Blackwell, John W.S. Bradshaw, Rachel A. Casey, Applied Animal Behaviour Science, published online 22 January 2013.
Defra Minister David Heath has announced the latest bute (phenylbutazone) test results. The presence of bute has been confirmed in 8 samples out of 206 tests.
Chief Medical Officer Professor Dame Sally Davies has stated that horsemeat containing phenylbutazone presents a very low risk to human health.
Responding to these latest developments the British Veterinary Association (BVA) and British Equine Veterinary Association (BEVA) have issued the following statement:
"The presence of phenylbutazone (or bute) in horses intended for the food chain will be of concern to consumers who rightly expect the UK food chain to be robust. We are grateful to the Chief Medical Officer for clarifying the very low level of risk that this presents to human health and we will work with the FSA and Defra in any way we can to assist their investigations into these incidents.
"The ability to treat horses with bute is very important for equine welfare. Bute provides affordable, long-term pain relief for horses and is unique in this respect.
"The UK Horse Passport Regulations are designed to facilitate the ongoing medical treatment of horses not intended for the human food chain, whilst ensuring that these animals do not enter the food chain.
"We fully support the concept of the Horse Passport Regulations but have argued for some time that there are problems with the system in terms of the number of Passport Issuing Authorities and the vulnerability of the system to fraud. We are very keen to continue our dialogue with Defra and others to find ways to make the system more robust.
"Our members are aware of the strict rules regarding the regulation of medicines (including bute) and the use of horse passports, and in recent years we have provided clear guidance on the regulations to help both vets and their clients. These incidents will hopefully reinforce these messages amongst horse owners and all of us involved in equine healthcare."
Guidance notes are available via the BEVA website Medicines Page (http://www.beva.org.uk/useful-info/Vets/Guidance/Medicines)
The Advertising Standards Authority has decided not to uphold complaints against the Morrisons Christmas TV advertisement.
The full adjudication can be read here.
Peter Jones, President of the British Veterinary Association, said: "This ruling is disappointing but the ASA has set out its reasons for the decision and we accept those reasons. Thankfully, the advert only had a short shelf life and we hope that Morrisons is now very unlikely to make the same mistakes again. Overall, we hope the whole incident has served to educate Morrisons and the general public about the dangers of grapes and raisins to dogs."
Invicta Animal Health has been appointed exclusive UK distributor of EquiChek, a rapid screening test which uses whole blood to assess the level of Serum Amyloid A (SAA), a major acute phase protein of inflammation in horses.
According to the company, EquiChek is the first test which is able to provide a visual semi-quantitative result within 15 minutes. The test will display 4 lines for a normal level of SAA and sequentially fewer lines depending on the severity of the inflammation.
Rob Watkins, Managing Director of Invicta, said: "Monitoring SAA levels in horses is a well-documented method of indicating a variety of conditions and for assessing health/inflammatory status prior to performance. However, the needs for equipment and time to perform the tests have always limited the situations in which it can be used.
"EquiChek changes all that. A stableside test for SAA means that monitoring real-time becomes a reality. Whether for tailoring antibiotic therapy, to check pre-breeding health status through to pre-competition health assessment, the applications are literally endless".
For further information see www.invictavet.com or phone 01403 791313
York-based Alstoe Animal Health, maker of Gleptosil and Vetergesic, has been acquired by French company Sogeval, a leading supplier of companion and livestock animal products.
Established in 1994, Alstoe was privatelv owned by the two original partners, John Nellis and lan Ryder.
For the last five years the company has been working with Sogeval to develop flavoured tablet pharmaceutical brands from Sogeval whilst the two companies have collaborated to make Vetergesic successful in France.
The business will continue to trade from the current premises for the foreseeable future and says it will maintain its high standard of customer service and product supply.
John Nellis said: "lt will be business as usual. We look forward to continued sales growth for our existing brands and the introduction of exciting new products in the future".
Dr. lan Ryder said: "Our companies have worked very well together in the past. The acquisition will bring fresh impetus to the business and ensure continued growth"
The current Alstoe team remains in place to assist with any enquiries. For further information contact info@alstoe.co.uk or telephone: 01347 878605
Life Technologies Animal Health has announced the launch of a new qPCR test to improve the diagnosis of mastitis and respiratory disease caused by Mycoplasma bovis.
According to the company, the TaqVet Mycoplasma Bovis (M. bovis) polymerase chain reaction (PCR) kit is based on a new target gene in the M. bovis genome and thus can distinguish better between infections caused by M. bovis and M. agalactiae - so there is less risk of false positive results and improved sensitivity and specificity.
The test is based on real-time PCR technology, and delivers results in two and a half hours.
Eric Sellal, Head of Animal Health EMEA at Life Technologies said: "The improved sensitivity of this new test means that veterinarians will be able to monitor dairy herds for sub-clinical infection using samples from the bulk tank. And of course it can also be used to diagnose mycoplasma infection in individual cases of clinical mastitis and respiratory disease."
Life Technologies says the test system incorporates a number of other improvements which simplify and speed up processing in the laboratory, including automatic extraction using magnetic bead technology.
It is estimated that bovine pneumonia costs the European industry around 500million Euros each year, with 30% accounted for by M. bovis. Other diseases associated with the organism include mastitis and arthritis.
Mycoplasma is slow and difficult to culture in the laboratory and current antibiotic treatment is not very cost-effective. Therefore, prevention is a cornerstone of M. bovis management.
The TaqVet Mycoplasma Bovis PCR kit will be made available in other EU countries and via Life Technologies Animal Health distributors according to local regulatory requirements (see www.lifetechnologies.com/lsi-animal-health) for details.
BCF Technology has launched the Sonosite Edge ultrasound system.
According to the company, the new system is suitable for both small animal and equine reproduction, abdominal, musculoskeletal, cardiac and ophthalmic applications.
The Sonosite Edge was apparently designed for use in battlefields and disaster zones, so it should withstand veterinary use. It is upgradeable to Colour, Pulsed Wave (PW) and Continuous Wave (CW) Doppler. It can also be DICOM enabled. It weighs 15kg and has a start up time of less than 15 seconds. There is a range of linear, mico-convex, convex and phased array probes available.
The system with one probe starts around £22,000.
Nigel Perry, BCF Account Manager said: "The Sonosite Edge offers an excellent system with superior image quality than has not been seen on a field-based system before. This is a perfect system for a mixed practice looking to perform a wide range of applications. It is very durable and can be taken anywhere."
To find out more about the Sonosite Edge, visit www.bcftechnology.co.uk or call +44(0)1506 460 023.
Veterinary surgeons have named their top new veterinary products of 2012 in a survey carried out by CM Research.
As part of the research, 343 vets working in UK practice were asked what they considered to be the best new product of 2012. Their answers were unprompted, and they were only allowed to mention one product or service. For this reason, some vets voted for products that were launched earlier than 2012. The full results were as follows:
Hill's y/dAn iodine restrictive hyperthyroid management food launched by Hill's Pet Nutrition in May 2012 won with an overwhelming 31% of the votes. www.hillspet.co.uk
Cardalis (CEVA Animal Health)Launched towards the end of 2012, CEVA's combined ACE inhibitor / spirolactone for heart failure in dogs scored a creditable 9.6% of mentions. www.ceva.co.uk
Seresto (Bayer Animal Health)Bayer's 8-month flea and tick collar came third with 6% of the votes. www.seresto.com.
Caninsulin Vetpen from MSDLaunched in July 2012, this new insulin delivery pen for Caninsulin is designed to improving dosing accuracy, consistency and ease of use. The user-friendly pen design is said to improve initial pet owner acceptance and on-going compliance.
Atopica Cat (Novartis Animal Health)Novartis launched Atopica Cat, an oral version of its treatment for chronic allergic dermatitis, at the start of 2012. www.itchfreepet.co.uk
Comfortis (Elanco)Launched in 2011, Comfortis is a novel oral flea adulticide for dogs which kills adult fleas rapidly for a month. www.comfortis.com
Nobivac Myxo RHD (MSD)The first vaccine to combine 12 months protection against both myxomatosis and rabbit haemorrhagic disease within a single inoculation. It is a non-adjuvanted vaccine which, according to MSD, delivers greater simplicity of protocol and enhanced disease protection.
Cimalgex (Vétoquinol)Launched towards the end of 2011, Vetoquinol's 2nd generation Cox-2 inhibitor is said by the company to be very well tolerated, have an excellent efficacy profile and be very easy to use, meaning that Cimalgex allows veterinary patients to benefit from pain relief in situations where clinicians would have been worried about the risks versus the benefits of prescribing a NSAID for pain management.
Activyl (MSD)MSD's novel flea spot-on is the first to work by bioactivation, only becoming an insecticide after being ingested by the flea, thus minimising owner's exposure to insecticides. Said to be effective against the other stages of the flea life cycle, too. www.activyl.co.uk
RevitaCAM (Abbott)RevitaCAM is the first and only veterinary NSAID (meloxicam) with oromucousal delivery. www.revitacam.co.uk.
Metacam for cats (Boehringer Ingelheim)Boehringer extended its Metacam 0.5 mg/ml Oral Suspension for Cats range with the launch of a 30ml bottle size in July. www.metacam.co.uk.
Zuprevo (MSD)MSD's antibiotic to combat bovine respiratory disease (BRD) was launched in the third quarter of 2011. www.zuprevo.com
V-Gel (Docsinnovent)V-gel was the first ever species-specific supraglottic airway device (pictured top right), currently available for cats and rabbits. Billed as the latest ground breaking technology for a safer anaesthesia, easier breathing and avoiding damage to the throat and trachea; a safer alternative to ET tubes. www.docsinnovent.com
Onsior (Novartis Animal Health)The tissue-selective oral and injectable Cox-2 inhibiting NSAID from Novartis was actually launched back in 2009.
Certifect (Merial)Merial's flea and tick spot-on for dogs was launched by Ray Mears in the UK in February 2012. www.certifect.co.uk
Calmex (VetPlus)Somewhat controversial when it made its first appearance in 2011, Calmex is a feed to help dogs and cats that may experience behavioural problems as a result of their environment or situations that may cause anxiety or fear. More info.
Comfortan (Dechra)The first licensed methadone for dogs was launched by Eurovet towards the end of 2011, before it was acquired by Dechra in May 2012. www.dechra.co.uk
Hill's Vet EssentialsHill's vet-exclusive petfood range is designed to meet essential dietary needs at every life stage. More info.
Trocoxil (Pfizer)Trocoxil, Pfizer's NSAID for canine osteoarthritis was remarkable for its once monthly dosage regime, when launched back in 2009.
VerafloxBayer launched its next generation fluoroquinolone antimicrobial for bacterial infections in cats and dogs at the end of 2011
YumoveYumove is a joint support supplement from Lintbells, containing glucosamine and chondroitin. More information.
The British Equine Veterinary Association (BEVA) has launched two guides to help veterinary professionals and their clients negotiate the complexities of equine insurance.
BEVA highlights that with up to 40% of horses becoming ill or injured in any one year and 25% of insured horses having a claim in any one year, vet fees insurance is a sensible way for horse owners to budget for unexpected healthcare costs.
The Veterinary Surgeon's guide to riding and sport horse insurance provides general guidelines to help vets understand the requirements and issues relating to equine insurance. It explains the three main types of insurance cover available: veterinary fees, death and permanent loss of use, as well as insurance recommendations for pre-purchase and pre-insurance vetting. The final section contains a jargon-busting guide to commonly used insurance terminology.
Complementing the vet guide is The BEVA leisure and sports horse Insurance Guide for horse owners, a handout for clients about to embark on taking out insurance. It covers the frequently asked questions relating to vets fees and death, including when and how to insure, the importance of pre-purchase vetting, exclusions and permanent loss of use.
Andrew Harrison, Junior Vice President of BEVA, said: "Whether a vet or a horse owner, understanding equine insurance can be intimidating for the best of us. The new guides should make it easier for you and your clients to understand the finer points of policies, premiums and claim protocols."
The guides can be downloaded from the BEVA website via the following links:
For additional information visit www.beva.org.uk
The British Small Animal Association has responded to Defra's statement on compulsory microchipping.
The Association says it is an advocate of compulsory microchipping as the most effective way to permanently identify a dog - as long as owners maintain an up-to-date registration on the various databases. As such it broadly welcomes the recent Defra statement.
However, BSAVA points out that the statement has come before a full and considered consultation in terms of its implementation, and says it raises a number of questions for vets in practice:
Despite the headlines around the statement, this is yet to be laid down in law and will require changes under the Animal Welfare Act and potentially the Dangerous Dogs Act, so there is still a conversation to be had about its implementation.
For this reason BSAVA has announced that it is launching a consultation with its members to establish their concerns and opinions in order to work with all the organisations involved in the best interest of animal welfare and the profession. If anyone in practice wants to feed into this consultation, they should visit http://www.bsava.com or contact BSAVA's Scientific Policy Officer Sally Everitt via email - s.everitt@bsava.com.
BSAVA President Mark Johnston said: "While implantation can be straightforward for those with appropriate experience it will be important to ensure that all those who carry out implantation are properly trained. However microchipping is not just a matter of implanting the microchip, there is a significant amount of administrative work in ensuring that animals are properly registered and that details are kept up-to-date. All of these stages need to be properly funded if the scheme is to be successful and sustainable. BSAVA will be consulting its members to gather their views and concerns and hope to be involved in a productive conversation with all interested parties."
BSAVA says there is a good news animal welfare story within this statement concerning the seizure of animals during investigation under the Dangerous Dogs Act. The new measures will allow the authorities to decide whether a suspected prohibited dog can stay with their owners until the outcome of court proceedings. Until now all such animals had to be kennelled until the proceedings had concluded, which often means that dogs who posed no risk suffered unnecessarily. BSAVA welcomes this new measure in the interest of animal welfare.